Literature DB >> 21600768

α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.

William D Shrader1, Akiko Amagata, Adam Barnes, Gregory M Enns, Andrew Hinman, Orion Jankowski, Viktoria Kheifets, Ryo Komatsuzaki, Edgar Lee, Paul Mollard, Katsuyuki Murase, Alfredo A Sadun, Martin Thoolen, Kieron Wesson, Guy Miller.   

Abstract

We report that α-tocotrienol quinone (ATQ3) is a metabolite of α-tocotrienol, and that ATQ3 is a potent cellular protectant against oxidative stress and aging. ATQ3 is orally bioavailable, crosses the blood-brain barrier, and has demonstrated clinical response in inherited mitochondrial disease in open label studies. ATQ3 activity is dependent upon reversible 2e-redox-cycling. ATQ3 may represent a broader class of unappreciated dietary-derived phytomolecular redox motifs that digitally encode biochemical data using redox state as a means to sense and transfer information essential for cellular function.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600768     DOI: 10.1016/j.bmcl.2011.04.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Bi-allelic CCDC47 Variants Cause a Disorder Characterized by Woolly Hair, Liver Dysfunction, Dysmorphic Features, and Global Developmental Delay.

Authors:  Marie Morimoto; Helen Waller-Evans; Zineb Ammous; Xiaofei Song; Kevin A Strauss; Davut Pehlivan; Claudia Gonzaga-Jauregui; Erik G Puffenberger; Charles R Holst; Ender Karaca; Karlla W Brigatti; Emily Maguire; Zeynep H Coban-Akdemir; Akiko Amagata; C Christopher Lau; Xenia Chepa-Lotrea; Ellen Macnamara; Tulay Tos; Sedat Isikay; Michele Nehrebecky; John D Overton; Matthew Klein; Thomas C Markello; Jennifer E Posey; David R Adams; Emyr Lloyd-Evans; James R Lupski; William A Gahl; May Christine V Malicdan
Journal:  Am J Hum Genet       Date:  2018-10-25       Impact factor: 11.025

2.  The LYR factors SDHAF1 and SDHAF3 mediate maturation of the iron-sulfur subunit of succinate dehydrogenase.

Authors:  Un Na; Wendou Yu; James Cox; Daniel K Bricker; Knut Brockmann; Jared Rutter; Carl S Thummel; Dennis R Winge
Journal:  Cell Metab       Date:  2014-06-19       Impact factor: 27.287

3.  Therapeutic strategies for Leber's hereditary optic neuropathy: A current update.

Authors:  Nuri Gueven; Dharmesh Faldu
Journal:  Intractable Rare Dis Res       Date:  2013-11

Review 4.  Otoprotectants: From Research to Clinical Application.

Authors:  Colleen G Le Prell
Journal:  Semin Hear       Date:  2019-04-26

Review 5.  Drug development for rare mitochondrial disorders.

Authors:  Orest Hurko
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 6.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

Review 7.  Clinical and molecular features of POLG-related mitochondrial disease.

Authors:  Jeffrey D Stumpf; Russell P Saneto; William C Copeland
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-04-01       Impact factor: 10.005

Review 8.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

Review 9.  Novel targets for mitochondrial medicine.

Authors:  Wang Wang; Georgios Karamanlidis; Rong Tian
Journal:  Sci Transl Med       Date:  2016-02-17       Impact factor: 17.956

Review 10.  Is there treatment for Leber hereditary optic neuropathy?

Authors:  Jason H Peragallo; Nancy J Newman
Journal:  Curr Opin Ophthalmol       Date:  2015-11       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.